Bio Medica LaboratoriesNSE:BMLL +0.49%14 EBITDA Margin % is 40.52% as of Mar. 2025, which is 8% above its 10-year median of 37.37. GuruFocus rates NSE:BMLL with a GF Score™ of 14/100. The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Bio Medica Laboratories ranks better than 96.45% on this metric.
Bio Medica Laboratories (NSE:BMLL) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Bio Medica Laboratories EBITDA Margin % Related Terms
Bio Medica Laboratories EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio Medica Laboratories EBITDA Margin % Chart
Bio Medica Laboratories Annual Data
Trend
Mar23
Mar24
Mar25
EBITDA Margin %
10.33
37.37
40.52
Bio Medica Laboratories Semi-Annual Data
Mar23
Mar24
Mar25
EBITDA Margin %
10.33
37.37
40.52
NSE:BMLL vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Bio Medica Laboratories's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio Medica Laboratories EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio Medica Laboratories's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Bio Medica Laboratories's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio Medica Laboratories (NSE:BMLL) has a EBITDA Margin % of 40.52% as of Mar. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bio Medica Laboratories and its competitors. This is near median its historical median of 37.37. Over the past decade, Bio Medica Laboratories' EBITDA Margin % has ranged from 10.33 to 40.52. According to the industry distribution chart, Bio Medica Laboratories ranks #29 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 3.6%.
Is Bio Medica Laboratories' EBITDA Margin % too high?
Bio Medica Laboratories' current EBITDA Margin % of 40.52% is near median its 10-year median of 37.37. Over the past 10 years, this metric has ranged from a low of 10.33 to a high of 40.52. The Medical Devices & Instruments industry median EBITDA Margin % is 7.39. Bio Medica Laboratories' value of 40.52% is 448.7% above this industry median. Based on the distribution chart, Bio Medica Laboratories ranks #29 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bio Medica Laboratories has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Bio Medica Laboratories' EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bio Medica Laboratories ranks #29 out of 816 companies for EBITDA Margin %. This places Bio Medica Laboratories in the top 4% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.39. Bio Medica Laboratories' value of 40.52% is 448.7% above this benchmark. Historically, Bio Medica Laboratories' own EBITDA Margin % has ranged from 10.33 to 40.52 over the past decade. While the company's 10-year median is 37.37 vs. the industry median of 7.39, Bio Medica Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.39, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio Medica Laboratories's current EBITDA Margin % of 40.52% is 448.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Bio Medica Laboratories and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio Medica Laboratories's current EBITDA Margin % is 40.52%, which is near median its own 10-year median of 37.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Medica Laboratories stock overvalued right now?
Bio Medica Laboratories (NSE:BMLL) has a current EBITDA Margin % of 40.52%. The current EBITDA Margin % is 40.52%, which is near median its 10-year median of 37.37 and 448.7% above the Medical Devices & Instruments industry median of 7.39. Bio Medica Laboratories' overall GF Score™ is 14/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Bio Medica Laboratories (NSE:BMLL), the current EBITDA Margin % is 40.52% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio Medica Laboratories Ltd is engaged in the manufacturing of Pharmaceutical Parenteral Formulations. It manufactures generic drugs in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Its products address a wide range of medical needs and preferences. The majority of revenue is derived from the sales of Liquid injections. Geographically, it operates predominantly in India, and internationally, it exports to Afghanistan.
14GF Score
Get the complete analysis for NSE:BMLL
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BMLL has been successfully added to your 